Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

NCT02027961 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Durvalumab
DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

MedImmune LLC